Merck (MRK) And Ridgeback Announce Publication of Phase 3 Study of Molnupiravir

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/27/2026

1. NVDA
2. OKTA
3. CRM
4. CRWD
5. VEEV
6. P
7. KKR
8. HPQ
9. NTNX
10. SNPS

Go back to Merck (MRK) And Ridgeback Announce Publication of Phase 3 Study of Molnupiravir
Merck & Co. (NYSE: MRK) Delayed: 149.54 -3.56 (2.33%)
Previous Close $153.10    52 Week High $65.46 
Open $149.53    52 Week Low $47.97 
Day High $152.08    P/E 101.73 
Day Low $149.02    EPS $1.47 
Volume 8,528,140